6/30/23, 12:05 AM UKPDS 33 Pathway Feedback Search Clinical Topics Home Studies UKPDS 33 UKPDS 33 Disease Diabetes mellitus type 2 Trial question Is intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or glipizide) or with insulin superior to conventional policy with diet? Study design Multi-center Open label RCT Population Characteristics of study participants 39.0% female N = 3867 61.0% male 3867 patients (1508 female, 2359 male) Inclusion criteria: patients with T2DM, median age 54 years, who after 3 months' diet treatment had a mean of two fasting plasma glucose concentrations of 6.1-15.0 mmol/L Key exclusion criteria: ketonuria > 3 mmol/L; serum creatinine > 175 mol/L; myocardial infarction in the previous year; current angina or HF; > 1 major vascular event; retinopathy requiring laser treatment; malignant hypertension; or uncorrected endocrine disorder Interventions N=2729 intensive blood-glucose treatment (with sulphonylurea, chlorpropamide, glibenclamide, or glipizide; or insulin, target FPG < 6 mmol/L) N=1138 conventional treatment (aim to best achieve FPG with diet alone) Primary outcome Incidence of diabetes-related events https://web.pathway.md/studies/recJrWQ5MbDj9SfEn 1/2 6/30/23, 12:05 AM UKPDS 33 Pathway 46.0/1000 py 46 40.9 34.5/1000 py 23.0/1000 py 11.5/1000 py Significant decrease 0.0/1000 py Intensive blood-glucose treatment Conventional treatment Significant decrease in the incidence of diabetes-related events (40.9 /1000 py vs. 46 /1000 py; RR 0.88, 95% CI 0.79 to 0.99) Secondary outcomes No significant difference in the incidence of diabetes-related death (10.4 /1000 py vs. 11.5 /1000 py; RR 0.9, 95% CI 0.73 to 1.11) No significant difference in the incidence of death from any cause (17.9 /1000 py vs. 18.9 /1000 py; RR 0.94, 95% CI 0.8 to 1.1) Safety outcomes Significant differences in hypoglycemic episodes (p < 0.0001) and weight gain (mean 2.9 kg, p < 0.001). Conclusion In patients with T2DM, median age 54 years, who after 3 months' diet treatment had a mean of two fasting plasma glucose concentrations of 6.1-15.0 mmol/L, intensive blood-glucose treatment was superior to conventional treatment with respect to the incidence of diabetes- related events. Reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Open reference URL https://web.pathway.md/studies/recJrWQ5MbDj9SfEn 2/2